Speech-Language Pathologists in Chateaugay, NY Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Mrs. Monalee Mary Siskavich, SPEECH PATHOLOGIST Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 42 River St, Bulldog Lane, Chateaugay, NY 12920 Phone: 518-497-6611 |
Kaitlin Grace Tebo, M.S.ED, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 42 River St, Chateaugay, NY 12920 Phone: 518-497-6611 Fax: 518-497-3170 |
Ms. Kathryn Ingrid Boyd, L/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 42 River St, Chateaugay, NY 12920 Phone: 518-497-6611 |
Mrs. Anne Marie Boyea, MA/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 42 River St, Chateaugay, NY 12920 Phone: 518-497-6290 |
News Archive
Thrombotech receives FDA IND approval for THR-18 Phase IIa clinical trial in stroke victims
Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.
Subdominant SARS-CoV-2 epitopes key to understanding emerging variants
Researchers in the UK have conducted a study showing the importance of considering subdominant epitopes within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when investigating neutralizing antibodies that target the virus.
Study sheds light on lingering effects of natural disasters, mass shootings and terrorist attacks
Repeated exposure to violent images from the terrorist attacks of September 11 and the Iraq War led to an increase in physical and psychological ailments in a nationally representative sample of U.S. adults, according to a new UC Irvine study.
PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million
PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.
Nastech Pharmaceutical awarded new breast cancer patent
Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."
› Verified 2 days ago
Speech-Language Pathologists
Occupational Therapists
Chiropractors